| FILANA THERAPEUTICS |
| USA |
| Gesundheit |
| US14817C1071 / A2PGL8 |
| PX91 (Frankfurt) / FLNA (NASDAQ) |
| FRA:PX91, ETR:PX91, PX91:GR, NASDAQ:FLNA |
| - |
| https://www.filanatx.com/ |
|
Filana Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing investigational therapies for central nervous system disorders. The company’s current work centers on simufilam, an oral small-molecule candidate being studie..
>Volltext.. |
| 31.23 Mio. EUR |
| -41.33 Mio. EUR |
| - |
| -39.21 Mio. EUR |
| -36.96 Mio. EUR |
| -0.76 EUR |
| - |
| 72.27 Mio. EUR |
| -25.09 Mio. EUR |
| 2.06 |
| - |
| 64.59% |
| - |
| - |
| - |
| - |
| FILANA THERAPEUTICS, FILANA THERAPEUTIC, CASSAVA SCIENCES |
| 23.09.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|